AmericanWell offers first telehealth SDK

Beth Walsh | | Health Exec | Telehealth

Telehealth provider American Well introduced the first-ever mobile Telehealth Software Development Kit (SDK) which allows any user to add online doctor visits into their native mobile apps.

“We believe one day every consumer will use telehealth with their doctor, and the SDK is our guarantee that future is imminent,” said Roy Schoenberg, MD, AmericanWell's CEO and co-founder.

Users have many options with in-app telehealth, according to the company, inlcuding healthcare management, online health information searches, prescription refills and medical compliance and adherence.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Related Content

Amazon One Medical sued after patient prescribed inhaler dies in ER
DEA, HHS extend telehealth controlled substance prescription rule
Association of 300 telehealth groups urges Congress to extend COVID-era rules
Eli Lilly releases cheaper, single-use vials of weight loss drug
Walmart sells virtual care business to Fabric
AMA will aggressively support permanent telemedicine reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.